霉酚酸暴露量临床评估

Assessment of Mycophenolic Acid Exposure in Clinic Practice

霉酚酸(Mycophenolateacid,MPA)可非竞争性地结合次黄嘌呤单核苷酸脱氢酶(Inosinemonophosphatedehydrogenase,IMPDH),抑制淋巴细胞增殖。临床将其前体药物霉酚酸酯作为免疫抑制剂,广泛应用于器官移植患者。由于霉酚酸治疗窗窄,影响其药物代谢因素较多,药动学个体差异较大,临床应用时必须监测霉酚酸血药浓度,将暴露量维持在有效范围内。本文就临床评估霉酚酸暴露量的方法做一综述,以期为临床合理用药提供参考。

Mycophenolic acid（MPA） inhibits lymphocyte proliferation through noncompetitive combination to inosine monophosphate dehydrogenase（IMPDH）.The prodrug mycophenolate mofetil is widely used in organ transplant patients as an immunosuppressive agent.The MPA plasma concentration must be monitored to help maintain its exposure within effective rang because of its narrow therapeutic window and individual differences in its metabolism and pharmacokinetics due to various factors.This article reviewed methods to assess MPA exposure in clinic,and hope to provide some useful information for rational drug using in clinic practice.